Networks & Communities | About ASCPT
ASCPT is a multi-disciplinary catalyst for emerging science committed to integrity and diversity. When you make a tax-free donation, you support clinical pharmacology and translational medicine for the safe and effective discovery, development, regulation, and utilization of medicines for improved patient care.
Members receive a complimentary subscription to Clinical Pharmacology & Therapeutics, the leading journal in the field of clinical pharmacology, in addition to the Open Access content of CPT: Pharmacometrics & Systems Pharmacology and Clinical and Translational Science. Members also obtain exclusive access to members-only webinars and the Webinar Library.
Members receive substantial discounts on ASCPT Annual Meeting registration rates and have the opportunity to further their connections through ASCPT’s Networks & Communities.
Members are encouraged to submit research and programming ideas to the ASCPT Annual Meeting, the ASCPT Journal Family, and the Webinar Program. Member can nominate themselves or a worthy colleague to serve on the Board of Directors.
There are a number of fraudulent list rental scams targeting scientific society meeting participants. If you receive any communications from someone claiming to sell our attendee list and/or manage our hotel information, please forward them to email@example.com so they can be tracked.
News, research, Networks, leadership opportunities and community
Clinical Pharmacology & Therapeutics
CPT: Pharmacometrics & Systems Pharmacology
Clinical and Translational Science
Schedules and event listings including webinars, podcasts and meetings.
Job seekers and employers review and post job listings and resumes
Comprehensive Support for ASCPT Members
Timely information to keep you up-to-date
Stay up to date with the latest information about clinical pharmacology, therapeutics, and translat... Read More...
With the Thursday, December 12, 2019 , Early Bird registration deadline quickly approaching, you... Read More...
FDA Approves ADAKVEO (Crizanlizumab-tmca) to Reduce the Frequency of Vasoocclusive Crises in ... Read More...